On October 14, 2026 Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, reported that the Company will highlight its multispecific platform in a presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting, being held November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Aptevo’s presentation will feature its broader CD40-directed multispecific portfolio and the Company’s approach to bringing together two critical arms of the immune system – innate and adaptive immunity – within the tumor microenvironment. Solid tumors can suppress or disrupt anti-tumor immune responses, limiting the ability of the immune system to recognize and effectively attack cancer. Aptevo’s tumor-directed CD40-activating molecules also act on the cells that mediate tumor cell killing and are designed to help overcome that challenge by localizing immune activation to the tumor and promoting a more complete anti-tumor response.
"We’re pleased to share progress from an important area of focus for Aptevo as we continue to expand the capabilities of our multispecific platform," said Mary Janatpour, PhD, Senior Vice President and Chief Scientific Officer of Aptevo. "Our multispecific technology is designed to bring complementary mechanisms together in a single molecule and create a deeper immune response within the tumor microenvironment. By combining tumor targeting with localized CD40 and T cell activation, we believe we have an opportunity to engage both innate and adaptive immunity where it matters most – at the tumor – while seeking to limit systemic immune activation. This work reflects the continued evolution of our platform and our strategy to build a next generation of multispecific therapies designed to address some of the most persistent challenges in solid tumors."
Presentation Details
Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting,
Title: Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor to overcome the immunosuppressive microenvironment and potentiate anti-tumor immunity
Abstract Number: 1060
Presenter: Michelle Nelson, PhD, et al
Date/Location: November 4-8, 2026, Phoenix Convention Center in Phoenix, Arizona
A copy of the presentation will be made available on the Publications page of the Aptevo website following its presentation at the meeting.
(Press release, Aptevo Therapeutics, OCT 14, 2026, View Source [SID1234673451])